EPIRUS Biopharmaceuticals, Inc. (Nasdaq: EPRS) 55.1% LOWER; announced reprioritization of the company’s pipeline to focus exclusively on developing biosimilars for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE